연구동향 분석
박사

면역관문억제제를 투여 받는 고형암 환자에서 인플루엔자 예방접종의 면역원성

강창경 2020년

논문상세정보
인용/피인용
' 면역관문억제제를 투여 받는 고형암 환자에서 인플루엔자 예방접종의 면역원성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • 면역관문억제제
  • 면역원성
  • 세포매개 면역반응
  • 예방접종
  • 인플루엔자
  • 체액성 면역반응
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,030 0

0.0%

' 면역관문억제제를 투여 받는 고형암 환자에서 인플루엔자 예방접종의 면역원성' 의 참고문헌

  • Vaccine applications of flow cytometry
    57:383-91 [2012]
  • Vaccination for seasonal influenza in patients with cancer : recommendations of the Italian Society of Medical Oncology ( AIOM )
    25:1243-7 [2014]
  • The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
    70:767-77 [1972]
  • The response to vaccination against influenza A ( H1N1 ) 2009 , seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab
    53:1212-20 [2014]
  • T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies
    34:3576-83 [2016]
  • Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus
    60:2438-47 [2009]
  • Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories
    23:236-42 [2016]
  • Serological immune responses to influenza vaccine in patients withColorectalCancer
    67:111-5 [2011]
  • Seroconversion after influenza vaccination in patients with lungCancer .
    80:219-20 [1999]
  • Safety of Inactivated Influenza Vaccine inCancer Patients Receiving ImmuneCheckpoint Inhibitors ( ICI )
    [2019]
  • Responses of patients with neoplastic diseases to influenza virus vaccine
    42:2244-7 [1978]
  • Randomized trial of influenza vaccine with granulocyte-macrophageColony-stimulating factor or placebo inCancer patients .
    20:4313-8 [2002]
  • Prevention andControl of seasonal influenza with vaccines : recommendations of the AdvisoryCommittee on Immunization Practices ( ACIP )
    [2009]
  • Prevention andControl of seasonal influenza with vaccines : Recommendations of the advisoryCommittee on immunization practices—united states , 2019–20 influenza season
    68:1-21 [2019]
  • Preexisting influenza-specificCD4+ TCellsCorrelate with disease protection against influenzaChallenge in humans
    18:274-80 [2012]
  • Polyfunctional T-Cell Signatures to Predict Protection fromCytomegalovirus after Lung Transplantation .
    193:78-85 [2016]
  • Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
    5 : e1248327 . [2016]
  • Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer .
    375:1823-33 [2016]
  • PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer
    35:169-78 [2012]
  • Overarching Immunodominance Patterns and Substantial Diversity in Specificity and Functionality in the Circulating Human Influenza A and B Virus-Specific CD4+ T-Cell Repertoire
    218:1169- 74 [2018]
  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma .
    377:1345-56 [2017]
  • Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles
    123:841-8 [2017]
  • Note for guidance on harmonization of requirements for influenza vaccines CPMP/BWP/214/96
    Available at : https : //www.ema.europa.eu/en/documents/scientific-guideline/noteguidance-harmonisation-requirements-influenza-vaccines_en.pdf . Accessed
  • Non-Small Cell Lung Cancer , Version 5.2017 , NCCN Clinical Practice Guidelines in Oncology
    15:504-35 [2017]
  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden .
    378:2093-104 [2018]
  • NCCN Guidelines Insights : Head and Neck Cancers , Version 1.2018
    16:479-90 [2018]
  • NCCN Guidelines Insights : Bladder Cancer , Version 5.2018
    16:1041-53 [2018]
  • Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
    13:843-50 [2007]
  • Management of ImmuneRelated Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline Summary
    14:247-9 [2018]
  • Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients : summary of ECIL-4 ( 2011 ) , on behalf of ECIL , a joint venture of EBMT , EORTC , ICHS , and ELN
    15:219-32 . [2013]
  • Leroux-Roels G. Influenza vaccines : Tcell responses deserve more attention
    11:949-62 [2012]
  • Kidney Cancer , Version 2.2017 , NCCN Clinical Practice Guidelines in Oncology
    15:804-34 [2017]
  • Influenza-specific lungresident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles
    128:721-33 [2018]
  • Influenza vaccines in immunosuppressed adults with cancer
    2 : CD008983 . [2018]
  • Influenza vaccination perception and coverage among patients with malignant disease
    33:1682-7 [2015]
  • Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events .
    0.277777777777778 [2018]
  • Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events .
    104:182-7 [2018]
  • Influenza vaccination in patients with breast cancer : a case-series analysis
    12 : CR332-6 . [2006]
  • Influenza vaccination in elderly patients with advanced colorectal cancer
    21:1161-6 [2003]
  • Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated antitumor function and indicates poor prognosis in digestive cancers .
    36:6143-53 [2017]
  • Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons : a single-center , parallel , randomized trial
    158:19-26 [2013]
  • Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients
    119:733 , -5 , 8 . [1978]
  • Immune checkpoint blockade : a common denominator approach to cancer therapy
    27:450-61 [2015]
  • IDSA clinical practice guideline for vaccination of the immunocompromised host .
    58 : e44-100 . [2013]
  • Humoral immune response after vaccination against influenza in patients with breast cancer
    9:65-8 [2001]
  • Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome
    0.590972222 [2012]
  • HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    107:4781-9 [2006]
  • H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients
    60:257-63 [2009]
  • Guidance for industry : toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials
    Available at : https : //www.fda.gov/index.php/media/73679/download . Accessed
  • Future prospects of immune checkpoint blockade in cancer : from response prediction to overcoming resistance
    50:109 [2018]
  • Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine ( FLU-v ) developed by SEEK : study protocol for a single-center , randomized , double-blind and placebo-controlled clinical phase IIb trial
    0.875694444 [2017]
  • Enhancement of antitumor immunity by CTLA-4 blockade .
    271:1734-6 [1996]
  • Effectiveness of MF59adjuvanted seasonal influenza vaccine in the elderly : A systematic review and meta-analysis
    35:513-20 [2017]
  • Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination .
    212:137-46 [2015]
  • Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine
    26:1990-8 [2008]
  • Cytokine production after influenza vaccination in a healthy elderly population
    16:1722-31 [1998]
  • Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults
    24 [2017]
  • Clinical practice . Prevention and treatment of seasonal influenza
    359:2579-85 [2008]
  • Clinical effectiveness of seasonal influenza vaccine among adult cancer patients
    119:4028-35 [2013]
  • Cell-mediated immune responses to influenza vaccination in Wegener 's granulomatosis .
    69:924-7 [2010]
  • Cell-Mediated Immune Responses after Influenza Vaccination of Solid Organ Transplant Recipients : a Secondary Outcomes Analysis of a Randomized Controlled Trial
    [2019]
  • Beare PA. Cytotoxic T-cell immunity to influenza .
    309:13-7 [1983]
  • Assessment of causality of individual adverse events following immunization ( AEFI ) : a WHO tool for global use
    31:5041-6 [2013]
  • Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine
    173:673-81 [2004]
  • A multicenter study of pandemic influenza A ( H1N1 ) infection in patients with solid tumors in 3 countries : early therapy improves outcomes
    118:4627-33 [2012]
  • 55. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ docs/ctcae_v5_quick_reference_5x7.pdf. Accessed 31 July 2019.
  • 3. Centers for Disease Control and Prevention. Cancer and Flu. Available at: https://www.cdc.gov/cancer/flu/. Accessed 26 Oct 2019.
  • 1. World Health Organization. Influenza (Seasonal). Available at: https://www.who.int/en/news-room/fact-sheets/detail/influenza- (seasonal). Accessed 26 Oct 2019.